Spiral Therapeutics
South San Francisco, US · Founded 2016 · Delaware corporation · 8 known investors
Find your way into Spiral Therapeutics
Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform. Its lead program, SPT-2101, is a sustained-release dexamethasone formulation for treating Ménière's disease.
Founders & leadership
Spiral Therapeutics was founded in 2016 by Hugo Peris.
HP
Hugo PerisinFounder · Chief Executive Officer
ED
Eugene de JuanNamed on SEC filing
LF
Lawrence FritzNamed on SEC filing
Board
Investors · 8
Catalio Capital Management✓ verifiedNew York
Alta PartnersreportedJackson · $1M – $12Mvia Guy Nohra · board
Esperante Venturesreported · 2 sourcesLondon · $540K – $5.4M
Inveready Technology Investment GroupreportedSan Sebastián · $108K – $21.6M
Also in the syndicate · 4
Advanced BionicsFerring VenturesGund InvestmentleadUni-Bio Science Group
Reported raises · per SEC filings
Form D private placements$46.5M disclosed across 3 rounds · 2018–2025
▶$27.1MraisedApr 2026 · 34 investors · PharmaceuticalsRule 506(b)
▶$27.1MraisedApr 2026 · 34 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- WARREN THALERDirector
- EUGENE DE JUANExecutive Officer, Director
- ANTHONY ADAMISDirector
- FREDERIC GUERARDDirector
- JEAN-FREDERIC PAULSENDirector
- GUY JEAN SAVOIR GARCIADirector
- HUGO PERISExecutive Officer, Director
- DIAMANTIS XYLASDirector
- ANGELA MACFARLANEDirector
- Offering amount
- $27.1M
- Amount sold
- $27.1M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.9MraisedFeb 2023 · 48 investors · Other Health CareRule 506(b)
▶$10.9MraisedFeb 2023 · 48 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- EUGENE DE JUANDirector
- GUY P. NOHRADirector
- ANGELA MACFARLANEDirector
- GUY JEAN SAVOIR GARCIADirector
- ANTHONY ADAMISDirector
- HUGO PERISExecutive Officer, Director
- DIAMANTIS XYLASDirector
- Offering amount
- $10.9M
- Amount sold
- $10.9M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedDec 2018 · 38 investors · Other Health CareRule 506(b)
▶$8.5MraisedDec 2018 · 38 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Eugene de JuanDirector
- Guy Jean Savoir GarciaDirector
- Hugo PerisExecutive Officer, Director
- Guy NohraDirector
- Lawrence FritzDirector
- Offering amount
- $12.9M
- Amount sold
- $8.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Spiral Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does Spiral Therapeutics do?
- Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform. Its lead program, SPT-2101, is a sustained-release dexamethasone formulation for treating Ménière's disease.
- Who founded Spiral Therapeutics?
- Spiral Therapeutics was founded by Hugo Peris in 2016.
- Who are Spiral Therapeutics's investors?
- Spiral Therapeutics's investors include Catalio Capital Management, Alta Partners, Esperante Ventures, Inveready Technology Investment Group.
- How much funding has Spiral Therapeutics raised?
- Spiral Therapeutics has disclosed $46.5M raised across 3 rounds.
- Where is Spiral Therapeutics headquartered?
- Spiral Therapeutics is headquartered in South San Francisco, US.